MITSUBISHI CORPORATION LIFE SCIENCES REVEALS CYSTEINE PEPTIDE INGESTION EFFECT ON SKIN BRIGHTNESS

KUALA LUMPUR, March 13 (Bernama) -- Mitsubishi Corporation Life Sciences Limited has published a new clinical study regarding the effect of ingestion of cysteine peptide containing glutathione on skin brightness.

In this study, the company defined glutathione (GSH), cysteinylglycine (Cys-Gly), and glutamylcysteine (-Glu-Cys) as cysteine peptide to investigate the effects of orally administered cysteine peptide on human skin brightness.

Mitsubishi Corporation Life Sciences in a statement said this study was designed to be a randomised, double-blind, placebo-controlled, parallel-group comparative study with healthy males and females aged between 20 and 65 years old.

Eligible participants were randomly allocated into three groups, with each subject ingested six tablets every day for 12 weeks, and skin brightness was measured using a portable spectrophotometer at screening, week zero, week four, week eight and week 12.

The result revealed that all groups showed a significant difference in arm brightness at 12 weeks compared to zero week.

The study showed that the group who orally took the cysteine peptide at 45 milligrammes (mg) for 12 weeks exhibited arm brightening in a time-dependent manner, and a significant difference was observed compared to the placebo at week 12.

Mitsubishi Corporation Life Sciences has an affiliate of KOHJIN Life Sciences, the manufacturer of Glutathione located in Japan with a history of over 70 years of production and it continues to strive towards the realisation of new value creation.

-- BERNAMA